智通财经网·2026-02-03 11:20Group 1 - The core point of the news is that Kangfang Biologics has signed an exclusive commercialization rights agreement with Jichuan Pharmaceutical, granting Jichuan the rights to market and sell the drug Yixinning® (Inusimab Injection) in mainland China [1] - Kangfang Biologics will receive a total of RMB 80 million (including tax) as an upfront licensing fee and up to RMB 10 million (including tax) in milestone payments from Jichuan Pharmaceutical [1] - Jichuan Pharmaceutical will be responsible for the commercialization and sales of Yixinning® in the authorized market [1] Group 2 - Yixinning® is an innovative PCSK9 monoclonal antibody developed by the company, approved for market in September 2024 for treating primary hypercholesterolemia and mixed dyslipidemia [2] - The drug has been included in the latest National Medical Insurance Directory and is highly recommended in the 2025 edition of expert consensus on managing cardiovascular risks related to blood lipids [2] - Yixinning® works by specifically binding to PCSK9 and blocking its interaction with LDL-R, thereby enhancing the clearance of LDL-C from plasma, which has shown significant efficacy in reducing cholesterol levels and lowering the risk of heart attacks and strokes [2]